LeonaBio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
58.5%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$3.12next fiscal year
Monitoring Framework
Key Performance Indicators
ELAINE-3 Phase 3 Clinical Trial Enrollment QuarterlyTarget: Complete enrollment in Q4 2026
ATH-1105 Phase 2 Proof-of-Concept Study Initiation QuarterlyTarget: Initiate study in ALS patients in 2H 2026
Cash Runway and Burn Rate Quarterly6,770.0%Target: Maintain sufficient capital to fund key clinical milestones
Watch Items
- Topline data readout for Phase 3 ELAINE-3 trial of lasofoxifeneTrigger: Expected in 2H 2027Action: Evaluate clinical efficacy and safety profile to support potential regulatory filing
- Clinical trial cost management and cash burnTrigger: Cash balance dropping below $30 millionAction: Assess additional financing options, including the potential exercise of cash-exercisable warrants
Research as of 24 Jul 2026